A Case of Long-Term Survival after Checkpoint Inhibitor Pneumonitis in a Patient with Squamous Cell Lung Cancer
The management of grade 1 checkpoint inhibitor pneumonitis (CIP) is to withhold immune checkpoint inhibitors; however, the natural history of this condition is unknown. We herein report the case of a woman with squamous cell lung cancer who was a long-term survivor after CIP. After 4 rounds of treat...
Saved in:
Main Authors: | Hironori Ashinuma, Satoko Mizuno, Yasushi Yoshida, Masato Shingyoji |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-01-01
|
Series: | Case Reports in Oncological Medicine |
Online Access: | http://dx.doi.org/10.1155/2019/4836404 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung
by: Samuel Kareff, et al.
Published: (2021-02-01) -
The impact of PD-L1 polymorphisms on the efficacy of immune checkpoint inhibitors depends on the tumor proportion score: a retrospective study
by: Keiichiro Suminaga, et al.
Published: (2025-02-01) -
Immune checkpoint inhibitor‐related type 1 diabetes incidence, risk, and survival association
by: Fumika Kamitani, et al.
Published: (2025-02-01) -
Airbag Pneumonitis
by: Raghav Govindarajan, et al.
Published: (2010-01-01) -
Impact of Immune Checkpoint Inhibitors and Local Radical Treatment on Survival Outcomes in Synchronous Oligometastatic NSCLC
by: Mandy Jongbloed, MD, et al.
Published: (2025-03-01)